Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2006 Jan;9(1):2-4.

Is Cyclin D1-CDK4 kinase a bona fide cancer target?

Author information

1
Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid E-28029, Spain. malumbres@cnio.es

Abstract

Previous studies have demonstrated that mice lacking Cyclin D1 were refractory to mammary tumor development induced by the c-neu/erbB-2 oncogene, the rodent ortholog of the HER-2 receptor frequently overexpressed in human breast carcinomas. Two new studies in this issue of Cancer Cell provide additional evidence on this issue. Knockin mice expressing a mutant form of Cyclin D1 that binds to Cdk4/6 but cannot activate their catalytic activity are resistant to c-neu/erbB-2 tumorigenesis in spite of undergoing normal epithelial cell expansion during pregnancy. Moreover, knockdown of Cdk4 in mammary tumor cells abrogates tumor formation. These observations provide new compelling evidence that inhibition of Cyclin D1-Cdk4/6 kinases might be beneficial for cancer therapy.

PMID:
16413464
DOI:
10.1016/j.ccr.2005.12.026
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center